BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37076132)

  • 21. Gastric neuroendocrine tumors in our institutions according to the WHO 2010 classification.
    Endo S; Dousei T; Yoshikawa Y; Hatanaka N; Taniyama K; Yamauchi A; Kamiike W; Nishijima J
    Int Surg; 2012; 97(4):335-9. PubMed ID: 23294075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neuroendocrine carcinoma of cervix: a clinicopathologic study of 82 cases].
    Feng M; Zou J; Zhang Y; Sun L
    Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):328-333. PubMed ID: 29783797
    [No Abstract]   [Full Text] [Related]  

  • 23. Comprehensive genetic features of gastric mixed adenoneuroendocrine carcinomas and pure neuroendocrine carcinomas.
    Koh J; Nam SK; Kwak Y; Kim G; Kim KK; Lee BC; Ahn SH; Park DJ; Kim HH; Park KU; Kim WH; Lee HS
    J Pathol; 2021 Jan; 253(1):94-105. PubMed ID: 32985687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Outcomes in Patients With Small- and Large-Cell Neuroendocrine Carcinoma (NEC) and Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm (MiNEN) of the Stomach.
    Choi NY; Kim BS; Oh ST; Yook JH; Kim BS
    Am Surg; 2021 Apr; 87(4):631-637. PubMed ID: 33142079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma.
    Lim SM; Kim H; Kang B; Kim HS; Rha SY; Noh SH; Hyung WJ; Cheong JH; Kim HI; Chung HC; Yun M; Cho A; Jung M
    Ann Nucl Med; 2016 May; 30(4):279-86. PubMed ID: 26837515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modified AJCC staging of gastric neuroendocrine carcinoma based on T staging can improve the capacity of prognosis assessment.
    Xie JW; Li P; Wang JB; Lin JX; Lu J; Chen QY; Yang YH; Kang DY; Zheng CH; Huang CM
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2391-2397. PubMed ID: 30209612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroendocrine Carcinoma of Gall Bladder: A Series of 19 Cases with Review of Literature.
    Kamboj M; Gandhi JS; Gupta G; Sharma A; Pasricha S; Mehta A; Chandragouda D; Sinha R
    J Gastrointest Cancer; 2015 Dec; 46(4):356-64. PubMed ID: 26208508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
    Merola E; Rinke A; Partelli S; Gress TM; Andreasi V; Kollár A; Perren A; Christ E; Panzuto F; Pascher A; Jann H; Arsenic R; Cremer B; Kaemmerer D; Kump P; Lipp RW; Agaimy A; Wiedenmann B; Falconi M; Pavel ME
    Ann Surg Oncol; 2020 May; 27(5):1348-1355. PubMed ID: 31720931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colonoscopy surveillance following adenoma removal to reduce the risk of colorectal cancer: a retrospective cohort study.
    Cross AJ; Robbins EC; Pack K; Stenson I; Kirby PL; Patel B; Rutter MD; Veitch AM; Saunders BP; Little M; Gray A; Duffy SW; Wooldrage K
    Health Technol Assess; 2022 May; 26(26):1-156. PubMed ID: 35635015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal surveillance strategies for patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model.
    Vale L; Kunonga P; Coughlan D; Kontogiannis V; Astin M; Beyer F; Richmond C; Wilson D; Bajwa D; Javanbakht M; Bryant A; Akor W; Craig D; Lovat P; Labus M; Nasr B; Cunliffe T; Hinde H; Shawgi M; Saleh D; Royle P; Steward P; Lucas R; Ellis R
    Health Technol Assess; 2021 Nov; 25(64):1-178. PubMed ID: 34792018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term surgical outcomes of gastric neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasms.
    Iwasaki K; Barroga E; Enomoto M; Tsurui K; Shimoda Y; Matsumoto M; Miyoshi K; Ota Y; Matsubayashi J; Nagakawa Y
    World J Surg Oncol; 2022 May; 20(1):165. PubMed ID: 35610656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinicopathological features and prognosis of patients with gastric neuroendocrine carcinoma from multiple centers in southern China].
    Fang C; Wang W; Zhang Y; Feng X; Zeng Y; Li Y; Chen J; Chen Y; Zhou Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1230-1234. PubMed ID: 27928791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma.
    Wei B; Ding T; Xing Y; Wei W; Tian Z; Tang F; Abraham S; Nayeemuddin K; Hunt K; Wu Y
    Cancer; 2010 Oct; 116(19):4463-73. PubMed ID: 20572042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for metastasis and survival of patients with T1 gastric neuroendocrine carcinoma treated with endoscopic therapy versus surgical resection.
    Ye H; Yuan Y; Chen P; Zheng Q
    Surg Endosc; 2022 Aug; 36(8):6162-6169. PubMed ID: 35507062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Subtype classification and clinicopathological characteristics of gastric neuroendocrine neoplasms: an analysis of 241 cases].
    Zhang P; Zhang Y; Zhang C; Shi Y; Liu J; Liu Q; Yu L; Wang M; Zou G; Lou J; Chen J; Tan H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1241-1246. PubMed ID: 27928793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.
    Choi E; Luo SJ; Ding VY; Wu JT; Kumar AV; Wampfler J; Tammemägi MC; Wilkens LR; Aredo JV; Backhus LM; Neal JW; Leung AN; Freedman ND; Hung RJ; Amos CI; Le Marchand L; Cheng I; Wakelee HA; Yang P; Han SS
    Cancer; 2024 Mar; 130(5):770-780. PubMed ID: 37877788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conversion surgery after extensive chemotherapy for stage IV mixed adenoneuroendocrine carcinoma (MANEC) of the gallbladder: clinical implications from the patterns of response and recurrence.
    Kamei K; Shindoh J; Kiya Y; Matsumoto I; Hashimoto M; Takeyama Y
    Clin J Gastroenterol; 2020 Apr; 13(2):240-246. PubMed ID: 31617127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prognostic analysis of 42 patients with gastric neuroendocrine carcinoma].
    Kou Y; Gao YB; Ma J; Yang K; Fu Q; Xie JG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):570-3. PubMed ID: 23801213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.